Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Oral Doses of BI 1323495 in Healthy Males
NCT03588390Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1323495 in Non-cystic fibrosis bronchiectasis (NCFB), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 15 days. Started Jul 2018; status: completed.
02
Drugs
BI 1323495
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)chronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03588390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588390.